Has the Taiwanese Biotech Industry valuation changed over the past few years?

Investors are relatively neutral on the industry at the moment, indicating that they anticipate long term growth rates to remain steady. The industry is trading close to its 3-year average PS ratio of 23.9x.

How does Taiwanese Biotech compare with similar industries?

There is insufficient data on the sub-industries of this industry.

Taiwanese (TAIEX) Biotech Industry Analysis

Date	Market Cap	Revenue	Earnings	PE
Thu, 30 Jun 2022	NT$550.2b	NT$22.5b	-NT$5,642,821,000.00	31.1x
Sat, 28 May 2022	NT$494.7b	NT$22.5b	-NT$5,642,821,000.00	31.8x
Mon, 25 Apr 2022	NT$541.4b	NT$21.5b	-NT$5,722,660,000.00	34.7x
Wed, 23 Mar 2022	NT$513.4b	NT$19.4b	-NT$4,874,140,000.00	28.3x
Fri, 18 Feb 2022	NT$466.6b	NT$17.9b	-NT$5,564,340,000.00	25.1x
Sun, 16 Jan 2022	NT$427.1b	NT$17.9b	-NT$5,532,702,000.00	25x
Tue, 14 Dec 2021	NT$466.7b	NT$17.9b	-NT$5,579,296,000.00	24.4x
Thu, 11 Nov 2021	NT$353.3b	NT$15.4b	-NT$7,624,179,000.00	20.9x
Sat, 09 Oct 2021	NT$343.8b	NT$15.4b	-NT$7,624,179,000.00	19.9x
Mon, 06 Sep 2021	NT$379.0b	NT$15.4b	-NT$7,624,179,000.00	22.7x
Wed, 04 Aug 2021	NT$400.1b	NT$15.4b	-NT$7,624,179,000.00	21.5x
Sat, 08 May 2021	NT$403.0b	NT$13.7b	-NT$8,453,670,500.00	26.8x
Tue, 09 Feb 2021	NT$272.0b	NT$13.4b	-NT$8,436,837,000.00	23.8x
Mon, 02 Nov 2020	NT$275.1b	NT$11.8b	-NT$10,319,873,500.00	78.3x
Thu, 06 Aug 2020	NT$290.5b	NT$11.2b	-NT$10,631,308,000.00	51.2x
Sun, 10 May 2020	NT$194.0b	NT$10.8b	-NT$10,916,068,500.00	61.2x
Sat, 01 Feb 2020	NT$202.7b	NT$10.4b	-NT$10,971,126,000.00	37.4x
Tue, 05 Nov 2019	NT$213.1b	NT$9.7b	-NT$11,320,634,500.00	33.1x
Fri, 09 Aug 2019	NT$233.8b	NT$9.3b	-NT$11,458,869,000.00	32.6x


TW Market	-0.49%
Healthcare	3.98%
Biotech	5.86%
Biotech	5.86%

Company	Last Price	7D	1Y	Valuation
6446 PharmaEssentia	NT$542.00	10.8% +NT$15.1b	524.4%	PS189.9x
6550 Polaris Group	NT$119.00	12.8% +NT$9.7b	63.2%	PS5688.3x
4142 Adimmune	NT$40.85	10.9% +NT$1.7b	-23.8%	PE301.2x
6617 Gongwin Biopharm Holdings	NT$284.50	5.6% +NT$1.6b	29.9%	PS27382.1x
4726 Mycenax Biotech	NT$43.00	18.1% +NT$1.0b	0.4%	PS9.4x

Jun 07

Senhwa Biosciences, Inc. Pindnarulex in Combination Study with Pfizer's Talazoparib for the Treatment of Prostate Cancer Granted Approval to Initiate from Australian HREC

Senhwa Biosciences, Inc. announced that it has received written approval from the Human Research Ethics Committee, Australia to begin a Phase I study evaluating Senhwa's Pidnarulex, the 2019 PCF-Pfizer Global Challenge Awards winner will be used in combination with Pfizer's PARP inhibitor, Talazoparib, to explore potential therapy in patients with metastatic The study will be conducted by Peter MacCallum Cancer Centre, Senhwa's clinical partner in Melbourne, Australia. This Phase I trial of Pidnarulex and Talazoparib will be mainly funded by the US Prostate Cancer Foundation and Pfizer. Senhwa will provide supplies of their study drug, Pidnarulex, in addition to some specific funding for the study.Pfizer's Talazoparib, an oral PARP inhibitor, received FDA's approval in October 2018 for the treatment of adults with deleterious or suspected deleterious germline BRCA mutation--positive, HER2-negative locally advanced or metastatic breast cancer. While BRCA1/2 deficient tumor cells are responsive to PARPi treatments, the development of PARPi resistance is common. In the previous Phase I trial conducted by CCTG, Senhwa's Pidnarulex demonstrated clinically significant and persist benefits in patients with specific tumor biomarkers, such as BRCA1/2, and PALB2 mutations, and who had been exposed to platinum and other chemotherapeutics. "Pidnarulex, alone, has shown efficacy in tumor cells resistant to PARPi in the preclinical studies. Therefore, think Pidnarulex demonstrates great potential as an alternative treatment for prostate cancer patients who have acquired resistance to PARPi or other chemotherapies," said Dr. John Soong, Chief Medical Officer of Senhwa Biosciences. Prostate Cancer is the second most lethal cancer for men in the United States. Although nearly 70% of patients can be cured with surgery, once the cancer has metastasized, almost all patients develop into castration-resistance, with a median survival time of less than two years. About Pidanrulex Specific mutations within the Homologous Recombination pathway may be exploited by Pidnarulex through a synthetic lethality approach by targeting the DNA repair defects in Homologous Recombination Deficiency tumors. Specifically, Pidnarulex is designed to stabilize DNA G-quadruplexes of cancer cells which leads to disruption of the cell's replication fork. While acting in concert with HR pathway deficiencies, such as BRCA1/2 mutations, replication forks stall and cause DNA breaks, ultimately resulting in cancer cell death. About Senhwa BiosciencesSenhwa Biosciences, Inc. is a drug development company focusing on the innovation of first-in-class DNA Damage Response therapeutics and addressing unmet medical needs in oncology. Headquartered in Taiwan, with an operational base in San Diego, California, Senhwa is well-positioned to oversee the development of its compounds. Silmitasertib and Pidnarulex, both with novel mechanisms of action as anti-cancer drugs for the treatment of multiple indications, are the core products in Senhwa Bioscience's pipeline. Clinical trials are currently ongoing in Australia, Canada, United States, Korea, and Taiwan.

Taiwanese (TAIEX) Biotech Industry Analysis

Industry Valuation and Performance

Industry Comparison

Top Stock Gainers and Losers

Latest News

4174

OBI Pharma, Inc. Announces Audit Committee Changes

6541

Tanvex BioPharma, Inc. Appoints Jang-Yang Chang as Independent Director

6550

Polaris Group Announces Initiation of Phase 3 Clinical Trials of Hepatocellular Carcinoma

6547

MVC File Provisional Approval Application of COVID-19 Vaccine to Therapeutic Goods Administration

6492

Senhwa Biosciences, Inc. Pindnarulex in Combination Study with Pfizer's Talazoparib for the Treatment of Prostate Cancer Granted Approval to Initiate from Australian HREC

6446

PharmaEssentia Corporation Receives Positive Recommendation from the DSMB to Continue the Phase III Clinical Trial of Ropeginterferon alfa-2b for Essential Thrombocythemia(ET)

4147

TaiMed Biologics Inc. Approves Board Appointments

4142

First quarter 2022 earnings: EPS misses analyst expectations

4726

First quarter 2022 earnings released: EPS: NT$0.12 (vs NT$0.85 in 1Q 2021)

4117

Investor sentiment deteriorated over the past week

4132

Full year 2021 earnings released: NT$3.35 loss per share (vs NT$3.11 loss in FY 2020)

6610

Full year 2021 earnings released: NT$0.23 loss per share (vs NT$1.51 loss in FY 2020)

6875

Pharmosa Biopharm Inc., Annual General Meeting, Jun 22, 2022

6617

Gongwin Biopharm Holdings Co., Ltd., Annual General Meeting, May 17, 2022

6696

We're Hopeful That Lin BioScience (GTSM:6696) Will Use Its Cash Wisely